<?xml version="1.0" ?>
<!DOCTYPE pmc-articleset PUBLIC "-//NLM//DTD ARTICLE SET 2.0//EN" "https://dtd.nlm.nih.gov/ncbi/pmc/articleset/nlm-articleset-2.0.dtd">

<pmc-articleset><article article-type="research-article" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink">
<?properties open_access?>
<front>
<journal-meta>
<journal-id journal-id-type="nlm-ta">JBRA Assist Reprod</journal-id>
<journal-id journal-id-type="iso-abbrev">JBRA Assist Reprod</journal-id>
<journal-id journal-id-type="publisher-id">jbra</journal-id>
<journal-title-group>
<journal-title>JBRA Assisted Reproduction</journal-title>
</journal-title-group>
<issn pub-type="ppub">1517-5693</issn>
<issn pub-type="epub">1518-0557</issn>
<publisher>
<publisher-name>Brazilian Society of Assisted Reproduction</publisher-name>
</publisher>
</journal-meta>
<article-meta>
<article-id pub-id-type="pmid">28967713</article-id>
<article-id pub-id-type="pmc">5714600</article-id>
<article-id pub-id-type="doi">10.5935/1518-0557.20170054</article-id>
<article-categories>
<subj-group subj-group-type="heading">
<subject>Original Article</subject>
</subj-group>
</article-categories>
<title-group>
<article-title>Reduction in the number of CGG repeats on the FMR1 gene in carriers
of genetic disorders versus noncarriers</article-title>
</title-group>
<contrib-group>
<contrib contrib-type="author">
<name>
<surname>Peyser</surname>
<given-names>Alexandra</given-names>
</name>
<xref ref-type="aff" rid="aff1">1</xref>
<xref ref-type="corresp" rid="c1"></xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Singer</surname>
<given-names>Tomer</given-names>
</name>
<xref ref-type="aff" rid="aff1">1</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Mullin</surname>
<given-names>Christine</given-names>
</name>
<xref ref-type="aff" rid="aff1">1</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Hershlag</surname>
<given-names>Avner</given-names>
</name>
<xref ref-type="aff" rid="aff1">1</xref>
</contrib>
<aff id="aff1">
<label>1</label>Department of Obstetrics and Gynecology, Northwell Health,
Division of Reproductive Endocrinology, Hofstra-Northwell School of Medicine,
New York, USA</aff>
</contrib-group>
<author-notes>
<corresp id="c1"><bold>Corresponding Author:</bold> Alexandra Peyser, Department of
Obstetrics and Gynecology, Northwell Health, Division of Reproductive
Endocrinology, Hofstra-Northwell School of Medicine, Manhasset, New York, USA,
E-mail: <email>peysera@gmail.com</email></corresp>
</author-notes>
<pub-date pub-type="epub-ppub">
<season>Oct-Dec</season>
<year>2017</year>
</pub-date>
<!--Fake ppub date generated by PMC from publisher
							pub-date/@pub-type='epub-ppub' -->
<pub-date pub-type="ppub">
<season>Oct-Dec</season>
<year>2017</year>
</pub-date>
<volume>21</volume>
<issue>4</issue>
<fpage>327</fpage>
<lpage>329</lpage>
<history>
<date date-type="received">
<day>13</day>
<month>4</month>
<year>2017</year>
</date>
<date date-type="accepted">
<day>05</day>
<month>8</month>
<year>2017</year>
</date>
</history>
<permissions>
<license license-type="open-access" xlink:href="http://creativecommons.org/licenses/by/4.0/">
<license-p>This is an Open Access article distributed under the terms of the
Creative Commons Attribution License, which permits unrestricted use,
distribution, and reproduction in any medium, provided the original work is
properly cited.</license-p>
</license>
</permissions>
<abstract>
<sec>
<title>Objective</title>
<p>CGG repeat expansion on the fragile X mental retardation 1 (FMR1) gene is
used to diagnose fragile X syndrome. Previous studies have discussed the
correlation between the number of CGG repeats and its associated phenotypic
components. The objective of this study is to determine whether the number
of CGG repeats differ between carriers of genetic disorders versus
noncarriers.</p>
</sec>
<sec>
<title>Methods</title>
<p>We performed a retrospective chart review of 2867 patients who received
genetic screening at our fertility clinic between June 2013 and July 2015.
The number of CGG repeats on allele 1 and allele 2 on the FMR1 gene was
collected and it was specified whether the patient was a carrier or a
noncarrier of a specific mutation. Patients with CGG repeats greater than or
equal to 45 were excluded from the study.</p>
</sec>
<sec>
<title>Results</title>
<p>Carriers (n=759) had a reduced number of repeats compared to noncarriers
(n=2024) on allele 1 (<italic>p</italic>=.03), allele 2
(<italic>p</italic>=.02) and the average of both alleles
(<italic>p</italic>=.01). Additionally, the number of CGG repeats from the
ten most carried diseases from the cohort were used and tested individually
for clinical significance against the number of repeats in the noncarriers.
A reduction in repeats was shown in several mutations and a few were
outliers.</p>
</sec>
<sec>
<title>Conclusion</title>
<p>Our results demonstrate that there is a significant reduction in the number
of CGG repeats in carriers of genetic mutations. A larger scale study of
disease carrying patients would be beneficial.</p>
</sec>
</abstract>
<kwd-group>
<kwd>FMR1</kwd>
<kwd>carrier screening</kwd>
<kwd>CGG repeats</kwd>
</kwd-group>
</article-meta>
</front>
<body>
<sec sec-type="intro">
<title>INTRODUCTION</title>
<p>The fragile X syndrome is one of the most common causes of inherited mental
retardation. The disorder is a result of intergenerational instability of a
trinucleotide CGG repeat expansion located on the 5' translated region of the
X-linked fragile X mental retardation 1 (FMR1) gene (<xref ref-type="bibr" rid="r2">Brown, 2002</xref>). The full mutation occurs when there are greater than 200
CGG repeats on the FMR1 gene, which results in the gene becoming fully methylated
and thus silenced. The numbers of CGG repeats fall into four categories based on
their stability: normal (up to 44 CGG repeats); intermediate (45-54 repeats);
premutation (55-200); and full mutation (&gt;200 repeats) (<xref ref-type="bibr" rid="r11">Maddalena <italic>et al</italic>., 2001</xref>). Some recent studies
have used a lower boundary to define the beginning of the intermediate stage (e.g.,
41 CGG repeats) (<xref ref-type="bibr" rid="r8">Hall <italic>et al</italic>.,
2011</xref>).</p>
<p>Repeat expansion in the "premutation" range, between 55 and 200, can cause distinct
clinical manifestations or neuropsychological changes. Disorders such as fragile
X-associated tremor/ataxia syndrome (FXTAS) and fragile X-associated premature
ovarian insufficiency have been associated with the premutation (<xref ref-type="bibr" rid="r10">Loesch &amp; Hagerman 2012</xref>).</p>
<p>Many studies have correlated the number of CGG repeats with a phenotypic presentation
(<xref ref-type="bibr" rid="r12">Mailick <italic>et al</italic>., 2014</xref>).
For example, studies have looked at whether the number of CGG repeats differs in
patients with Parkinson's Disease, Essential Tremor, and Multiple Sclerosis (<xref ref-type="bibr" rid="r3">Cilia <italic>et al</italic>., 2009</xref>; <xref ref-type="bibr" rid="r4">Clark <italic>et al</italic>., 2015</xref>; <xref ref-type="bibr" rid="r16">Zhang <italic>et al</italic>., 2009</xref>). Patients
with the premutation alleles have been described to have additional phenotypic
components such as developmental problems, autism spectrum disorders, attention
deficit hyperactivity disorders, shyness, anxiety and seizures. Fibromyalgia and
hypothyroidism have also been found to be more common in carriers of the premutation
compared to controls (<xref ref-type="bibr" rid="r14">Rodriguez-Revenga et
al.,2009</xref>; <xref ref-type="bibr" rid="r13">Roberts et al., 2009</xref>;
<xref ref-type="bibr" rid="r9">Hessl et al., 2005</xref>; <xref ref-type="bibr" rid="r1">Bourgeois et al., 2011</xref>; <xref ref-type="bibr" rid="r5">Coffeyet
al., 2008</xref>).</p>
<p>A lower-than-normal range of CGG has been associated with a myriad of clinical
presentations, ranging from increased thirst and memory loss to a higher incidence
of breast and uterine cancer, as well as increased risk of having a child with
developmental impairment or mental disability (<xref ref-type="bibr" rid="r12">Mailick <italic>et al</italic>., 2014</xref>).</p>
<p>Only a few studies have examined the relationship between CGG repeats and the
genotypic makeup of patients. BRCA1/2 mutation carriers have been shown to have
distinctly lower CGG repeats compared to the general population (<xref ref-type="bibr" rid="r15">Weghofer <italic>et al</italic>., 2012</xref>). It has
been theorized that BRCA1/2 mutations may be embryo-lethal, unless rescued by low
CGG repeats in the FMR1 genes. However, this assumption has been disputed by other
studies (<xref ref-type="bibr" rid="r6">Dagan <italic>et al</italic>.,
2014</xref>).</p>
<p>The objective of this study is to determine whether the number of CGG repeats differs
between carriers of various genetic disorders compared to noncarriers.</p>
</sec>
<sec sec-type="materials|methods">
<title>MATERIALS AND METHODS</title>
<p>Genetic screening results were collected from women that came into our fertility
clinic between June 2013 and July 2015. Genetic screening was done on a blood sample
from the patient and it was tested for mutations in 102 clinically significant genes
(Counsyl<sup>®</sup>, San Francisco, CA., USA). The number of CGG repeats
on allele 1 and allele 2 of the FMR1 gene was also obtained from the genetic
results, as well as whether the patient was a carrier or a noncarrier of one or
several gene mutations. Patients with CGG repeats greater or equal to 45 were
excluded from the study due to the potential of those with the ‘intermediate’ number
to have Fragile X. The averages of the CGG repeats on allele 1 and allele 2 were
obtained for carriers and noncarriers.</p>
<p>Additionally, the ten most carried diseases within our center were obtained and the
CGG distribution for each disease was collected. The ten most carried diseases were:
Hb Beta Chain-Related Hemoglobinopathy, Cystic Fibrosis, Pseudocholinesterase
Deficiency, Spinal Muscular Atrophy, Alpha-1 Antitrypsin Deficiency, GJB2-related
DFNB1 nonsyndromic hearing loss and deafness, Gaucher Disease, Familial
Mediterranean Fever, Smith-Lemli-Opitz Syndrome and Achromatopsia. The average of
the CGG repeats for carriers of genetic diseases was tested for clinical
significance and compared to the noncarriers. The CGG distribution for each disease
was also individually tested for significance against noncarriers.</p>
<p>Triple repeat detection was done by PCR to size the CGG repeat in the 5' UTR region
of the FMR1 (NM_002024.4: c.1-131CGG[1_n]). PCR products generated from
fluorescently labeled primers are detected by gel electrophoresis. Reported sizes
are accurate to +/- 1 repeat for up to 200 repeats. All laboratory investigations
were performed using commercial assays (Counsyl<sup>®</sup>, San Francisco,
Ca., USA).</p>
<p>The distribution of the CGG repeats in women with and without a carrier mutation was
compared using the statistical t-test when appropriate, at 5% significance
level.</p>
</sec>
<sec sec-type="results">
<title>RESULTS</title>
<p>In total, the study included 2,867 women who received genetic screening. Of those,
843 (mean age 35.9±5.4y) were carriers of one or more genetic diseases, and
2024 (mean age 35.7±5.0y) were noncarriers. 84 women were excluded from the
carrier cohort because they had CGG repeats greater than or equal to 45. Therefore,
759 carriers of a genetic mutation were included in the study.</p>
<p><xref ref-type="table" rid="t1">Table 1</xref> outlines the average number of CGG
repeats for carriers, noncarriers and the top ten carrier mutations at our center.
Carriers had lower CGG repeat values compared to noncarriers for allele 1
(<italic>p</italic>=.03), allele 2 (<italic>p</italic>=.02) and the average of
both alleles (<italic>p</italic>=.01). Allele 1 repeats in carriers of Alpha-1
Antitrypsin, Gaucher, Familial Mediterranean Fever and Smith-Lemli-Opitz Syndrome
had significantly lower repeats than noncarriers. (<italic>p</italic>=.01,
<italic>p</italic>=.02, <italic>p</italic>=.02, <italic>p</italic>=.01,
respectively). Allele 2 repeats in carriers of Alpha-1 Antitrypsin, Gaucher and
Smith-Lemli-Opitz Syndrome had lower repeats than noncarriers
(<italic>p</italic>=.02, <italic>p</italic>=.01, <italic>p</italic>=.05,
respectively). The average of both allele 1 and allele 2 in Alpha-1 Antitrypsin,
Gaucher and Smith-Lemli-Opitz Syndrome carriers demonstrated significantly reduced
CGG repeats than noncarriers. (<italic>p</italic>=.003, <italic>p</italic>=.004,
<italic>p</italic>=.009). No significant difference was noted in any of the
other CGG distributions within the other diseases.</p>
<table-wrap id="t1" orientation="portrait" position="float">
<label>Table 1</label>
<caption>
<p>Average number of CGG repeats for carriers and noncarriers on allele 1,
allele 2 and the average of alleles 1 and 2. </p>
</caption>
<table frame="box" rules="all">
<colgroup span="1">
<col span="1" width="25%"/>
<col span="1" width="25%"/>
<col span="1" width="25%"/>
<col span="1" width="25%"/>
</colgroup>
<thead>
<tr>
<th align="left" colspan="1" rowspan="1">Disease</th>
<th align="center" colspan="1" rowspan="1">CGG Allele 1 (Mean)</th>
<th align="center" colspan="1" rowspan="1">CGG Allele 2 (Mean)</th>
<th align="center" colspan="1" rowspan="1">Avg. of Both Alleles</th>
</tr>
</thead>
<tbody>
<tr>
<td align="left" colspan="1" rowspan="1">Hb Beta <italic>(n=93)</italic></td>
<td align="center" colspan="1" rowspan="1">28.20±3.7</td>
<td align="center" colspan="1" rowspan="1">31.58±4.0</td>
<td align="center" colspan="1" rowspan="1">29.90±3.3</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1">Cystic Fibrosis <italic>(n=90)</italic></td>
<td align="center" colspan="1" rowspan="1">27.92±3.6</td>
<td align="center" colspan="1" rowspan="1">31.39±3.6</td>
<td align="center" colspan="1" rowspan="1">29.66±3.0</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1">Pseudocholinesterase <italic>(n=65)</italic></td>
<td align="center" colspan="1" rowspan="1">27.62±4.2</td>
<td align="center" colspan="1" rowspan="1">31.97±4.2</td>
<td align="center" colspan="1" rowspan="1">29.79±3.3</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1">SMA <italic>(n=48)</italic></td>
<td align="center" colspan="1" rowspan="1">28.23±3.7</td>
<td align="center" colspan="1" rowspan="1">31.06±2.9</td>
<td align="center" colspan="1" rowspan="1">29.65±2.4</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1">GJB2 <italic>(n=47)</italic></td>
<td align="center" colspan="1" rowspan="1">27.60±4.2</td>
<td align="center" colspan="1" rowspan="1">31.21±4.7</td>
<td align="center" colspan="1" rowspan="1">29.40±3.7</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1">Gaucher <italic>(n=43)</italic></td>
<td align="center" colspan="1" rowspan="1">26.51+ 4.7</td>
<td align="center" colspan="1" rowspan="1">30.33±3.3</td>
<td align="center" colspan="1" rowspan="1">28.42±3.4</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1">Alpha-1 Antitrypsin <italic>(n=39)</italic></td>
<td align="center" colspan="1" rowspan="1">26.41±4.9</td>
<td align="center" colspan="1" rowspan="1">30.41±3.3</td>
<td align="center" colspan="1" rowspan="1">28.41±3.5</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1">Smith-Lemli-Opitz Syndrome <italic>(n=35)</italic></td>
<td align="center" colspan="1" rowspan="1">26.43±4.3</td>
<td align="center" colspan="1" rowspan="1">30.60±2.3</td>
<td align="center" colspan="1" rowspan="1">28.51±2.7</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1">FMF <italic>(n=34)</italic></td>
<td align="center" colspan="1" rowspan="1">26.41±4.8</td>
<td align="center" colspan="1" rowspan="1">31.74±4.1</td>
<td align="center" colspan="1" rowspan="1">29.10±3.6</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1">Achromatopsia <italic>(n=30)</italic></td>
<td align="center" colspan="1" rowspan="1">28.87±3.4</td>
<td align="center" colspan="1" rowspan="1">31.00±2.9</td>
<td align="center" colspan="1" rowspan="1">29.93±2.3</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1">Noncarriers <italic>(n=2024)</italic></td>
<td align="center" colspan="1" rowspan="1">27.82±3.9</td>
<td align="center" colspan="1" rowspan="1">31.55±3.5</td>
<td align="center" colspan="1" rowspan="1">29.69±3.3</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1">Carriers <italic>(n=759)</italic></td>
<td align="center" colspan="1" rowspan="1">27.50±4.3</td>
<td align="center" colspan="1" rowspan="1">31.25±3.6</td>
<td align="center" colspan="1" rowspan="1">29.37±3.2</td>
</tr>
</tbody>
</table>
<table-wrap-foot>
<fn id="TFN1">
<p>Abbreviations: Hb-Beta, Hb Beta Chain-Related Hemoglobinopathy;</p>
</fn>
<fn id="TFN2">
<p>SMA, Spinal Muscular Atrophy;</p>
</fn>
<fn id="TFN3">
<p>GJB2, GJB2-related DFNB1 nonsyndromic hearing loss and deafness;</p>
</fn>
<fn id="TFN4">
<p>FMF, Familial Mediterranean Fever.</p>
</fn>
</table-wrap-foot>
</table-wrap>
</sec>
<sec sec-type="discussion">
<title>DISCUSSION</title>
<p>This study evaluated whether there is a correlation between the numbers of CGG
repeats in carriers of genetic mutations versus noncarriers, to determine whether
CGG repeats differ between the two groups. We evaluated 2867 women who were screened
for genetic mutations. Overall, carriers had a lower number of CGG repeats than
noncarriers. However, several mutations were outliers. <xref ref-type="bibr" rid="r15">Weghofer <italic>et al</italic>. (2012)</xref> described an
association between low CGG repeats and BRCA1/2 positive women. They suggested that
low numbers of CGG’s rescued embryos carrying the BRCA1/2 mutation. If a human
embryo carries a low allele (&lt;26), then the embryo is able to overcome the
BRCA1/2- associated embryo lethality. Additionally, they hypothesized that BRCA1/2
mutations may somehow be able to influence CGG repeat expansion.</p>
<p>Another trinucleotide pattern, the CAG repeat, has been found to be associated with a
higher risk of cryptorchidism in patients with shorter repeats. It has been
hypothesized that there is an indirect influence whereby the shorter CAG repeats
create lower testosterone levels and, therefore, influence the androgen receptor
mediated genomic pathway associated with cryptorchidism (<xref ref-type="bibr" rid="r7">Davis-Dao <italic>et al</italic>., 2012</xref>).</p>
<p>The mechanism by which the carrier status can cause a reduction in the number of CGG
repeats or vice-versa could be a result of an indirect relationship between the
transcription of the FMR1 gene and the genes responsible for the carrier mutation.
Mechanistic investigations are needed to identify these indirect or direct
effects.</p>
<p>A limitation to our study is the small sample size. Indeed, a larger cohort with more
carriers would be beneficial.</p>
<p>In conclusion, this preliminary investigation suggests that carriers of genetic
mutations have less CGG repeats on the FMR1 gene when compared to noncarriers.
Larger epidemiological studies of disease carrying patients as well as analysis of
genomic pathway mechanisms may be beneficial.</p>
</sec>
<sec>
<title>HUMAN STUDIES AND INFORMED CONSENT STATEMENT</title>
<p>All procedures followed were in accordance with the ethical standards of the
responsible committee on human experimentation (institutional and national) and with
the Helsinki Declaration of 1975, as revised in 2000. Informed consent was obtained
from all patients for being included in the study. The Northwell Health
Institutional Review Board reviewed and approved this study.</p>
</sec>
</body>
<back>
<ref-list>
<title>REFERENCES</title>
<ref id="r1">
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Bourgeois</surname>
<given-names>JA</given-names>
</name>
<name>
<surname>Seritan</surname>
<given-names>AL</given-names>
</name>
<name>
<surname>Casillas</surname>
<given-names>EM</given-names>
</name>
<name>
<surname>Hessl</surname>
<given-names>D</given-names>
</name>
<name>
<surname>Schneider</surname>
<given-names>A</given-names>
</name>
<name>
<surname>Yang</surname>
<given-names>Y</given-names>
</name>
<name>
<surname>Kaur</surname>
<given-names>I</given-names>
</name>
<name>
<surname>Cogswell</surname>
<given-names>JB</given-names>
</name>
<name>
<surname>Nguyen</surname>
<given-names>DV</given-names>
</name>
<name>
<surname>Hagerman</surname>
<given-names>RJ</given-names>
</name>
</person-group>
<article-title>Lifetime prevalence of mood and anxiety disorders in fragile X
premutation carriers</article-title>
<source/>J Clin Psychiatry
          <year>2011</year>
<volume>72</volume>
<fpage>175</fpage>
<lpage>182</lpage>
<pub-id pub-id-type="doi">10.4088/JCP.09m05407blu</pub-id>
<pub-id pub-id-type="pmid">20816038</pub-id>
</element-citation>
</ref>
<ref id="r2">
<element-citation publication-type="book">
<person-group person-group-type="author">
<name>
<surname>Brown</surname>
<given-names>WT</given-names>
</name>
</person-group>
<chapter-title>The Molecular Biology of the Fragile X Mutation</chapter-title>
<person-group person-group-type="editor">
<name>
<surname>Hagerman</surname>
<given-names>R</given-names>
</name>
<name>
<surname>Hagerman</surname>
<given-names>PJ</given-names>
</name>
</person-group>
<source/>Fragile X Syndrome: Diagnosis, Treatment, and Research
          <edition>3rd ed.</edition>
<publisher-loc>Baltimore</publisher-loc>
<publisher-name>Johns Hopkins University Press</publisher-name>
<year>2002</year>
<fpage>110</fpage>
<lpage>135</lpage>
</element-citation>
</ref>
<ref id="r3">
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Cilia</surname>
<given-names>R</given-names>
</name>
<name>
<surname>Kraff</surname>
<given-names>J</given-names>
</name>
<name>
<surname>Canesi</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Pezzoli</surname>
<given-names>G</given-names>
</name>
<name>
<surname>Goldwurm</surname>
<given-names>S</given-names>
</name>
<name>
<surname>Amiri</surname>
<given-names>K</given-names>
</name>
<name>
<surname>Tang</surname>
<given-names>HT</given-names>
</name>
<name>
<surname>Pan</surname>
<given-names>R</given-names>
</name>
<name>
<surname>Hagerman</surname>
<given-names>PJ</given-names>
</name>
<name>
<surname>Tassone</surname>
<given-names>F</given-names>
</name>
</person-group>
<article-title>Screening for the presence of FMR1 premutation alleles in women
with parkinsonism</article-title>
<source/>Arch Neurol
          <year>2009</year>
<volume>66</volume>
<fpage>244</fpage>
<lpage>249</lpage>
<pub-id pub-id-type="doi">10.1001/archneurol.2008.548</pub-id>
<pub-id pub-id-type="pmid">19204162</pub-id>
</element-citation>
</ref>
<ref id="r4">
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Clark</surname>
<given-names>LN</given-names>
</name>
<name>
<surname>Ye</surname>
<given-names>X</given-names>
</name>
<name>
<surname>Liu</surname>
<given-names>X</given-names>
</name>
<name>
<surname>Louis</surname>
<given-names>ED</given-names>
</name>
</person-group>
<article-title>Genetic analysis of FMR1 repeat expansion in essential
tremor</article-title>
<source/>Neurosci Lett
          <year>2015</year>
<volume>593</volume>
<fpage>114</fpage>
<lpage>117</lpage>
<pub-id pub-id-type="doi">10.1016/j.neulet.2015.03.027</pub-id>
<pub-id pub-id-type="pmid">25796179</pub-id>
</element-citation>
</ref>
<ref id="r5">
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Coffey</surname>
<given-names>SM</given-names>
</name>
<name>
<surname>Cook</surname>
<given-names>K</given-names>
</name>
<name>
<surname>Tartaglia</surname>
<given-names>N</given-names>
</name>
<name>
<surname>Tassone</surname>
<given-names>F</given-names>
</name>
<name>
<surname>Nguyen</surname>
<given-names>DV</given-names>
</name>
<name>
<surname>Pan</surname>
<given-names>R</given-names>
</name>
<name>
<surname>Bronsky</surname>
<given-names>HE</given-names>
</name>
<name>
<surname>Yuhas</surname>
<given-names>J</given-names>
</name>
<name>
<surname>Borodyanskaya</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Grigsby</surname>
<given-names>J</given-names>
</name>
<name>
<surname>Doerflinger</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Hagerman</surname>
<given-names>PJ</given-names>
</name>
<name>
<surname>Hagerman</surname>
<given-names>RJ</given-names>
</name>
</person-group>
<article-title>Expanded clinical phenotype of women with the FMR1
premutation</article-title>
<source/>Am J Med Genet A
          <year>2008</year>
<volume>146A</volume>
<fpage>1009</fpage>
<lpage>1016</lpage>
<pub-id pub-id-type="doi">10.1002/ajmg.a.32060</pub-id>
<pub-id pub-id-type="pmid">18348275</pub-id>
</element-citation>
</ref>
<ref id="r6">
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Dagan</surname>
<given-names>E</given-names>
</name>
<name>
<surname>Cohen</surname>
<given-names>Y</given-names>
</name>
<name>
<surname>Mory</surname>
<given-names>A</given-names>
</name>
<name>
<surname>Adir</surname>
<given-names>V</given-names>
</name>
<name>
<surname>Borochowitz</surname>
<given-names>Z</given-names>
</name>
<name>
<surname>Raanani</surname>
<given-names>H</given-names>
</name>
<name>
<surname>Kurolap</surname>
<given-names>A</given-names>
</name>
<name>
<surname>Melikhan-Revzin</surname>
<given-names>S</given-names>
</name>
<name>
<surname>Meirow</surname>
<given-names>D</given-names>
</name>
<name>
<surname>Gershoni-Baruch</surname>
<given-names>R</given-names>
</name>
</person-group>
<article-title>BRCA1/2 mutations and FMR1 alleles are randomly distributed: a
case control study</article-title>
<source/>Eur J Hum Genet
          <year>2014</year>
<volume>22</volume>
<fpage>277</fpage>
<lpage>279</lpage>
<pub-id pub-id-type="doi">10.1038/ejhg.2013.281</pub-id>
<pub-id pub-id-type="pmid">24281364</pub-id>
</element-citation>
</ref>
<ref id="r7">
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Davis-Dao</surname>
<given-names>C</given-names>
</name>
<name>
<surname>Koh</surname>
<given-names>CJ</given-names>
</name>
<name>
<surname>Hardy</surname>
<given-names>BE</given-names>
</name>
<name>
<surname>Chang</surname>
<given-names>A</given-names>
</name>
<name>
<surname>Kim</surname>
<given-names>SS</given-names>
</name>
<name>
<surname>De Filippo</surname>
<given-names>R</given-names>
</name>
<name>
<surname>Hwang</surname>
<given-names>A</given-names>
</name>
<name>
<surname>Pike</surname>
<given-names>MC</given-names>
</name>
<name>
<surname>Carroll</surname>
<given-names>JD</given-names>
</name>
<name>
<surname>Coetzee</surname>
<given-names>GA</given-names>
</name>
<name>
<surname>Vandenberg</surname>
<given-names>D</given-names>
</name>
<name>
<surname>Siegmund</surname>
<given-names>K</given-names>
</name>
<name>
<surname>Cortessis</surname>
<given-names>VK</given-names>
</name>
</person-group>
<article-title>Shorter androgen receptor CAG repeat lengths associated with
cryptorchidism risk among Hispanic white boys</article-title>
<source/>J Clin Endocrinol Metab
          <year>2012</year>
<volume>97</volume>
<fpage>E393</fpage>
<lpage>E399</lpage>
<pub-id pub-id-type="doi">10.1210/jc.2011-2439</pub-id>
<pub-id pub-id-type="pmid">22188741</pub-id>
</element-citation>
</ref>
<ref id="r8">
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Hall</surname>
<given-names>DA</given-names>
</name>
<name>
<surname>Berry-Kravis</surname>
<given-names>E</given-names>
</name>
<name>
<surname>Zhang</surname>
<given-names>W</given-names>
</name>
<name>
<surname>Tassone</surname>
<given-names>F</given-names>
</name>
<name>
<surname>Spector</surname>
<given-names>E</given-names>
</name>
<name>
<surname>Zerbe</surname>
<given-names>G</given-names>
</name>
<name>
<surname>Hagerman</surname>
<given-names>PJ</given-names>
</name>
<name>
<surname>Ouyang</surname>
<given-names>B</given-names>
</name>
<name>
<surname>Leehey</surname>
<given-names>MA</given-names>
</name>
</person-group>
<article-title>FMR1 gray-zone alleles: association with Parkinson's disease in
women?</article-title>
<source/>Mov Disord
          <year>2011</year>
<volume>26</volume>
<fpage>1900</fpage>
<lpage>1906</lpage>
<pub-id pub-id-type="doi">10.1002/mds.23755</pub-id>
<pub-id pub-id-type="pmid">21567456</pub-id>
</element-citation>
</ref>
<ref id="r9">
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Hessl</surname>
<given-names>D</given-names>
</name>
<name>
<surname>Tassone</surname>
<given-names>F</given-names>
</name>
<name>
<surname>Loesch</surname>
<given-names>DZ</given-names>
</name>
<name>
<surname>Berry-Kravis</surname>
<given-names>E</given-names>
</name>
<name>
<surname>Leehey</surname>
<given-names>MA</given-names>
</name>
<name>
<surname>Gane</surname>
<given-names>LW</given-names>
</name>
<name>
<surname>Barbato</surname>
<given-names>I</given-names>
</name>
<name>
<surname>Rice</surname>
<given-names>C</given-names>
</name>
<name>
<surname>Gould</surname>
<given-names>E</given-names>
</name>
<name>
<surname>Hall</surname>
<given-names>DA</given-names>
</name>
<name>
<surname>Grigsby</surname>
<given-names>J</given-names>
</name>
<name>
<surname>Wegelin</surname>
<given-names>JA</given-names>
</name>
<name>
<surname>Harris</surname>
<given-names>S</given-names>
</name>
<name>
<surname>Lewin</surname>
<given-names>F</given-names>
</name>
<name>
<surname>Weinberg</surname>
<given-names>D</given-names>
</name>
<name>
<surname>Hagerman</surname>
<given-names>PJ</given-names>
</name>
<name>
<surname>Hagerman</surname>
<given-names>RJ</given-names>
</name>
</person-group>
<article-title>Abnormal elevation of FMR1 mRNA is associated with psychological
symptoms in individuals with the fragile X premutation</article-title>
<source/>Am J Med Genet B Neuropsychiatr Genet
          <year>2005</year>
<volume>139B</volume>
<fpage>115</fpage>
<lpage>121</lpage>
<pub-id pub-id-type="doi">10.1002/ajmg.b.30241</pub-id>
<pub-id pub-id-type="pmid">16184602</pub-id>
</element-citation>
</ref>
<ref id="r10">
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Loesch</surname>
<given-names>D</given-names>
</name>
<name>
<surname>Hagerman</surname>
<given-names>R</given-names>
</name>
</person-group>
<article-title>Unstable mutations in the FMR1 gene and the
phenotypes</article-title>
<source/>Adv Exp Med Biol
          <year>2012</year>
<volume>769</volume>
<fpage>78</fpage>
<lpage>114</lpage>
<pub-id pub-id-type="pmid">23560306</pub-id>
</element-citation>
</ref>
<ref id="r11">
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Maddalena</surname>
<given-names>A</given-names>
</name>
<name>
<surname>Richards</surname>
<given-names>CS</given-names>
</name>
<name>
<surname>Mcginniss</surname>
<given-names>MJ</given-names>
</name>
<name>
<surname>Brothman</surname>
<given-names>A</given-names>
</name>
<name>
<surname>Desnick</surname>
<given-names>RJ</given-names>
</name>
<name>
<surname>Grier</surname>
<given-names>RE</given-names>
</name>
<name>
<surname>Hirsch</surname>
<given-names>B</given-names>
</name>
<name>
<surname>Jacky</surname>
<given-names>P</given-names>
</name>
<name>
<surname>McDowell</surname>
<given-names>GA</given-names>
</name>
<name>
<surname>Popovich</surname>
<given-names>B</given-names>
</name>
<name>
<surname>Watson</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Wolff</surname>
<given-names>DJ</given-names>
</name>
</person-group>
<article-title>Technical standards and guidelines for fragile X: the first of a
series of disease-specific supplements to the Standards and Guidelines for
Clinical Genetics Laboratories of the American College of Medical Genetics.
Quality Assurance Subcommittee of the Laboratory Practice
Committee</article-title>
<source/>Genet Med
          <year>2001</year>
<volume>3</volume>
<fpage>200</fpage>
<lpage>205</lpage>
<pub-id pub-id-type="doi">10.1097/00125817-200105000-00010</pub-id>
<pub-id pub-id-type="pmid">11388762</pub-id>
</element-citation>
</ref>
<ref id="r12">
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Mailick</surname>
<given-names>MR</given-names>
</name>
<name>
<surname>Hong</surname>
<given-names>J</given-names>
</name>
<name>
<surname>Rathouz</surname>
<given-names>P</given-names>
</name>
<name>
<surname>Baker</surname>
<given-names>MW</given-names>
</name>
<name>
<surname>Greenberg</surname>
<given-names>JS</given-names>
</name>
<name>
<surname>Smith</surname>
<given-names>L</given-names>
</name>
<name>
<surname>Maenner</surname>
<given-names>M</given-names>
</name>
</person-group>
<article-title>Low-normal FMR1 CGG repeat length: phenotypic
associations</article-title>
<source/>Front Genet
          <year>2014</year>
<volume>5</volume>
<fpage>309</fpage>
<lpage>309</lpage>
<pub-id pub-id-type="doi">10.3389/fgene.2014.00309</pub-id>
<pub-id pub-id-type="pmid">25250047</pub-id>
</element-citation>
</ref>
<ref id="r13">
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Roberts</surname>
<given-names>JE</given-names>
</name>
<name>
<surname>Bailey</surname>
<given-names>DB</given-names>
<suffix>Jr</suffix>
</name>
<name>
<surname>Mankowski</surname>
<given-names>J</given-names>
</name>
<name>
<surname>Ford</surname>
<given-names>A</given-names>
</name>
<name>
<surname>Sideris</surname>
<given-names>J</given-names>
</name>
<name>
<surname>Weisenfeld</surname>
<given-names>LA</given-names>
</name>
<name>
<surname>Heath</surname>
<given-names>TM</given-names>
</name>
<name>
<surname>Golden</surname>
<given-names>RN</given-names>
</name>
</person-group>
<article-title>Mood and anxiety disorders in females with the FMR1
premutation</article-title>
<source/>Am J Med Genet B Neuropsychiatr Gene
          <year>2009</year>
<volume>150B</volume>
<fpage>130</fpage>
<lpage>139</lpage>
<pub-id pub-id-type="doi">10.1002/ajmg.b.30786</pub-id>
<pub-id pub-id-type="pmid">18553360</pub-id>
</element-citation>
</ref>
<ref id="r14">
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Rodriguez-Revenga</surname>
<given-names>L</given-names>
</name>
<name>
<surname>Madrigal</surname>
<given-names>I</given-names>
</name>
<name>
<surname>Pagonabarraga</surname>
<given-names>J</given-names>
</name>
<name>
<surname>Xunclà</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Badenas</surname>
<given-names>C</given-names>
</name>
<name>
<surname>Kulisevsky</surname>
<given-names>J</given-names>
</name>
<name>
<surname>Gomez</surname>
<given-names>B</given-names>
</name>
<name>
<surname>Milà</surname>
<given-names>M</given-names>
</name>
</person-group>
<article-title>Penetrance of FMR1 premutation associated pathologies in fragile
X syndrome families</article-title>
<source/>Eur J Hum Genet
          <year>2009</year>
<volume>17</volume>
<fpage>1359</fpage>
<lpage>1362</lpage>
<pub-id pub-id-type="doi">10.1038/ejhg.2009.51</pub-id>
<pub-id pub-id-type="pmid">19367323</pub-id>
</element-citation>
</ref>
<ref id="r15">
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Weghofer</surname>
<given-names>A</given-names>
</name>
<name>
<surname>Tea</surname>
<given-names>MK</given-names>
</name>
<name>
<surname>Barad</surname>
<given-names>DH</given-names>
</name>
<name>
<surname>Kim</surname>
<given-names>A</given-names>
</name>
<name>
<surname>Singer</surname>
<given-names>CF</given-names>
</name>
<name>
<surname>Wagner</surname>
<given-names>K</given-names>
</name>
<name>
<surname>Gleicher</surname>
<given-names>N</given-names>
</name>
</person-group>
<article-title>BRCA1/2 mutations appear embryo-lethal unless rescued by low (CGG
n&lt;26) FMR1 sub-genotypes: explanation for the 'BRCA
paradox'?</article-title>
<source/>PLoS One
          <year>2012</year>
<volume>7</volume>
<elocation-id>e44753</elocation-id>
<pub-id pub-id-type="doi">10.1371/journal.pone.0044753</pub-id>
<pub-id pub-id-type="pmid">22984553</pub-id>
</element-citation>
</ref>
<ref id="r16">
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Zhang</surname>
<given-names>L</given-names>
</name>
<name>
<surname>Coffey</surname>
<given-names>S</given-names>
</name>
<name>
<surname>Lua</surname>
<given-names>LL</given-names>
</name>
<name>
<surname>Greco</surname>
<given-names>CM</given-names>
</name>
<name>
<surname>Schafer</surname>
<given-names>JA</given-names>
</name>
<name>
<surname>Brunberg</surname>
<given-names>J</given-names>
</name>
<name>
<surname>Borodyanskaya</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Agius</surname>
<given-names>MA</given-names>
</name>
<name>
<surname>Apperson</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Leehey</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Tartaglia</surname>
<given-names>N</given-names>
</name>
<name>
<surname>Tassone</surname>
<given-names>F</given-names>
</name>
<name>
<surname>Hagerman</surname>
<given-names>PJ</given-names>
</name>
<name>
<surname>Hagerman</surname>
<given-names>RJ</given-names>
</name>
</person-group>
<article-title>FMR1 premutation in females diagnosed with multiple
sclerosis</article-title>
<source/>J Neurol Neurosurg Psychiatr
          <year>2009</year>
<volume>80</volume>
<fpage>812</fpage>
<lpage>814</lpage>
<pub-id pub-id-type="doi">10.1136/jnnp.2008.160960</pub-id>
<pub-id pub-id-type="pmid">19531693</pub-id>
</element-citation>
</ref>
</ref-list>
</back>
</article>
</pmc-articleset>